Suche
Mein Konto
Men and women respond similarly and positively to treatment of heart failure with dapagliflozin
In heart failure (HF), sex differences are known to influence everything from risk factors to clinical presentation to treatment response, making sex a key factor to consider in studies of new pharmacotherapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin have emerged as an important pharmacotherapeutic solution for patients with heart failure, but more data are needed to evaluate their efficacy and safety between genders. Investigators at Brigham and Women's Hospital, a founding member of the Mass General Brigham Health System, conducted a study to address this knowledge gap by conducting a prespecified pooled analysis of DAPA-HF on...
Men and women respond similarly and positively to treatment of heart failure with dapagliflozin
In heart failure (HF), sex differences are known to influence everything from risk factors to clinical presentation to treatment response, making sex a key factor to consider in studies of new pharmacotherapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin have emerged as an important pharmacotherapeutic solution for patients with heart failure, but more data are needed to evaluate their efficacy and safety between genders.
Investigators at Brigham and Women's Hospital, a founding member of the Mass General Brigham Health System, conducted a study to address this knowledge gap by conducting a prespecified patient-level pooled analysis of DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure). Clinical outcomes for 11,007 randomized patients, 35 percent of whom were women, were compared by gender across the spectrum of left ventricular ejection fraction. In both DAPA-HF and DELIVER, men and women responded similarly and positively to dapagliflozin on the primary outcomes of worsening heart failure or cardiovascular death and the secondary outcomes of general health status.
Given the consistency of our study with other SGLT2 inhibitor trials such as EMPEROR, gender-specific indications for this class of heart failure therapies may not be needed in the future. We are pleased that dapagliflozin was safe and well tolerated in both genders, with improved clinical outcomes and health status.”
Xiaowen (Wendy) Wang, MD, lead author, Department of Cardiovascular Medicine
Source:
Reference:
Wang, X., et al. (2022) Sex differences in characteristics, outcomes and response to treatment with dapagliflozin across the ejection fraction range in patients with heart failure: insights from DAPA-HF and DELIVER. Traffic. doi.org/10.1161/CIRCULATIONAHA.122.062832.
.